Abbott Laboratories Net Income 2010-2022 | ABT
Abbott Laboratories annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
- Abbott Laboratories net income for the quarter ending March 31, 2022 was $2.447B, a 36.48% increase year-over-year.
- Abbott Laboratories net income for the twelve months ending March 31, 2022 was $7.725B, a 34.96% increase year-over-year.
- Abbott Laboratories annual net income for 2021 was $7.071B, a 57.31% increase from 2020.
- Abbott Laboratories annual net income for 2020 was $4.495B, a 21.91% increase from 2019.
- Abbott Laboratories annual net income for 2019 was $3.687B, a 55.7% increase from 2018.
Abbott Laboratories Annual Net Income
(Millions of US $) |
| 2021 |
$7,071 |
| 2020 |
$4,495 |
| 2019 |
$3,687 |
| 2018 |
$2,368 |
| 2017 |
$477 |
| 2016 |
$1,400 |
| 2015 |
$4,423 |
| 2014 |
$2,284 |
| 2013 |
$2,576 |
| 2012 |
$5,963 |
| 2011 |
$4,728 |
| 2010 |
$4,626 |
| 2009 |
$5,746 |
Abbott Laboratories Quarterly Net Income
(Millions of US $) |
| 2022-03-31 |
$2,447 |
| 2021-12-31 |
$1,989 |
| 2021-09-30 |
$2,100 |
| 2021-06-30 |
$1,189 |
| 2021-03-31 |
$1,793 |
| 2020-12-31 |
$2,162 |
| 2020-09-30 |
$1,232 |
| 2020-06-30 |
$537 |
| 2020-03-31 |
$564 |
| 2019-12-31 |
$1,049 |
| 2019-09-30 |
$960 |
| 2019-06-30 |
$1,006 |
| 2019-03-31 |
$672 |
| 2018-12-31 |
$654 |
| 2018-09-30 |
$563 |
| 2018-06-30 |
$733 |
| 2018-03-31 |
$418 |
| 2017-12-31 |
$-828 |
| 2017-09-30 |
$603 |
| 2017-06-30 |
$283 |
| 2017-03-31 |
$419 |
| 2016-12-31 |
$798 |
| 2016-09-30 |
$-329 |
| 2016-06-30 |
$615 |
| 2016-03-31 |
$316 |
| 2015-12-31 |
$767 |
| 2015-09-30 |
$580 |
| 2015-06-30 |
$784 |
| 2015-03-31 |
$2,292 |
| 2014-12-31 |
$905 |
| 2014-09-30 |
$538 |
| 2014-06-30 |
$466 |
| 2014-03-31 |
$375 |
| 2013-12-31 |
$590 |
| 2013-09-30 |
$966 |
| 2013-06-30 |
$476 |
| 2013-03-31 |
$544 |
| 2012-12-31 |
$1,053 |
| 2012-09-30 |
$1,943 |
| 2012-06-30 |
$1,725 |
| 2012-03-31 |
$1,242 |
| 2011-12-31 |
$1,619 |
| 2011-09-30 |
$303 |
| 2011-06-30 |
$1,943 |
| 2011-03-31 |
$864 |
| 2010-12-31 |
$1,441 |
| 2010-09-30 |
$891 |
| 2010-06-30 |
$1,292 |
| 2010-03-31 |
$1,003 |
| 2009-12-31 |
$1,539 |
| 2009-09-30 |
$1,480 |
| 2009-06-30 |
$1,288 |
| 2009-03-31 |
$1,439 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Products Manufacturing |
$192.394B |
$43.075B |
|
Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
|
